Article

A19 - Perioperative Mechanical Circulatory Support for Improved Outcomes in High-risk Coronary Artery Bypass Grafting

Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image
Average (ratings)
No ratings
Your rating

Received:

Accepted:

Published online:

Correspondence Details:Nathan J Smith, njsmith@mcw.edu

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Background: Coronary artery bypass grafting (CABG) is the ideal revascularisation strategy for patients with complex coronary artery disease. While beneficial in patients with severe left ventricular dysfunction (LVD; ejection fraction [EF] <35%), this patient group presents a disproportionately high risk for postoperative mortality.

Hypothesis: Perioperative mechanical circulatory support (MCS) instituted for patients with severe LVD undergoing CABG will mitigate the occurrence of a low output state (LOS) and improve postoperative outcomes.

Methods: Seven patients with ischaemic cardiomyopathy and severe LVD presented with various stages of heart failure. Each underwent uncomplicated CABG with a preoperative microaxial (n=4) or durable (n=3) LVAD. Four patients met Medicare criteria for durable LVAD; three received a device during CABG. The remaining patients received a microaxial device prior to or at the time of CABG. An historical cohort of 61 patients who underwent conventional CABG was used for comparison.

Results: All microaxial patients survived to device explant. One died on day 12 postoperation due to aspiration. All durable LVAD patients were alive at latest follow-up, with one patient undergoing successful device explant after 302 days, with a recovered EF of 50%. Both microaxial (3.12 l/min, p=0.02) and durable LVAD (3.20 l/min, p=0.02) recipients demonstrated a significantly higher cardiac index 24 hours post-CABG compared to control patients (2.58 l/min).

Microaxial patients demonstrated equivalent time to vasopressor independence (1,877 versus 2,942 minutes, p=0.63), lactate normalisation (5 versus 373 minutes, p=0.30) and 24-hour vasoactive-inotropic score (VIS; 6.1 versus 3.9, p=0.52) compared to control patients. Durable LVAD, patients required vasopressors longer (7,336 versus 2,942 minutes, p<0.001), but had comparable lactate normalisation time and VIS. Length of stay was significantly longer for both microaxial and durable LVAD groups compared to controls. Primary device-related complications were gastrointestinal bleeding and reoperation for bleeding.

Conclusion: Perioperative MCS allows for improved haemodynamic support and mitigates the occurrence of LOS in patients with severe LVD undergoing CABG.